

FIG. 1





FIG. 2

Platform Technology Relevance Ratio Input



	310	320	330	Comments
Technology is scalable.	N/A			
Technology is amenable for automation.	No			
Technology does not require specialized instrumentation.	N/A			
Technology does not require special facilities.	N/A			
Technology requires less than 1 week of training.	Yes			
Technology requires specialized training.	N/A			
Technology does not require expert know-how.	Yes			
Quality control measures have been established for contracted services.	No			
Contracted service has built-in security/confidentiality.	N/A			
Contracted service is customized for small scale projects.	N/A			
Contracted service is customized for mass production.	No			
Data, resulting from the use of your technology, has been published in internationally recognized journals.	N/A			
Technology is pre-packaged.	Yes			
Technology is packaged as a kit.	N/A			
System is portable across platforms.	N/A			
System is available for demo.	N/A			
System is available for a feasibility study.	Yes			
System is amenable to multi-disciplinary use.	N/A			
System upgrades are seamless, no downtime, data compatibility assured.	Yes			
24 hour system support is available.	N/A			
System supports global multi-site usage.	N/A			

CONTINUE TO NON-CONFIDENTIAL PACKET

300

340

FIG. 3




FIG. 4




Figure 1 consists of 12 line graphs, labeled (a) through (l), arranged vertically. Each graph plots a different physiological or behavioral parameter over a 10-minute period. The y-axis for all graphs ranges from 0 to 100. The x-axis for all graphs ranges from 0 to 10 minutes. The graphs show a general decrease in values during the intervention period, with some parameters showing a more pronounced decrease than others. The parameters are: (a) Heart rate (b/min), (b) Blood pressure (mmHg), (c) Blood flow (ml/min), (d) Blood flow (ml/min), (e) Blood flow (ml/min), (f) Blood flow (ml/min), (g) Blood flow (ml/min), (h) Blood flow (ml/min), (i) Blood flow (ml/min), (j) Blood flow (ml/min), (k) Blood flow (ml/min), and (l) Blood flow (ml/min).

Priorities		514
	Platform Technology Opportunity	
		Y or N or N/A 660-1
		Y or N or N/A 660-2
		⋮
		Y or N or N/A 660-Z
	Discovery Search	
		Y or N or N/A 660-1
		Y or N or N/A 660-2
		⋮
		Y or N or N/A 660-Z
	PreClinical	
	Clinical	
	Marketed Product	
	Opportunity Type1	
	Opportunity Type 2	
	⋮	

FIG. 6

7/29




FIG. 7

Post a Platform Technology Opportunity



Product Destination: 810

Territories Available: 830 830

☐ United States ☐ All Europe ☐ Part of Europe ☐ Canada ☐ Japan ☐ Other 820

ETO Status: Please select one 870

ETO Status: Please select one 880

JPO Status: Please select one 890

Technology Field: 840

Licensees: 850

Application: 860

Comments:

**All mandatory fields should be filled before continuing to Relevance Ratio questions.*

CONTINUE TO RELEVANCE RATIO QUESTIONS

SAVE WORK IN PROGRESS

804

808

800

FIG. 8

TOP SECRET 13595260

9/29

Post a Platform Technology Opportunity



Product Description:

Territories Available:

☐ United States ☐ All Europe ☐ Part of Europe ☐ Canada ☐ Japan ☐ Other

PTO Status:

Issued - Life Remaining 5-10 years ▾

Please select one

Provisional - Filed

Formal - Filed

Issued - Life Remaining < 5 years

Issued - Life Remaining 5-10 years

Issued - Life Remaining > 10 years

Issued - Expired

Not Filed

900

Technical Field:

Licenses(s):*

910

FIG. 9

Non-Confidential Packet

FILES AVAILABLE FOR DOWNLOAD



Product Designation: **rfg**

1010

Language

[Click here to download the Non-Confidential Template](#)

[Click here to download the Confidential Template](#)

Add New Files to Packet

File

Title

Contents

Language


Brief Description

1020

1030

1040

FIG. 10



12/29





FIG. 11B

1200

13/29

My Company Opportunities



Platform Technology Opportunities

Add New Platform Technology

Product Designation	Technology Field	Application	Times Viewed	Unique Viewers	Status	Go To
TestDC	PTO	drug screening	0	0	Lister Work In Progress	Edit View
TestDC	PTO	drug screening	0	0	Lister Work In Progress	Edit View
Test	Test	Test	0	0	Lister Work In Progress	Edit View
NewTest	Widget	Topical	16	4	Submitted To BioStreet.com	Edit View

Discovery Research Opportunities

Add New Discovery Research

Product Designation	Times Viewed	Unique Viewers	Status	Go To
TestProductOfPennieAndEdmunds	0	0	Lister Work In Progress	Edit View
TBD1234	101	18	Active	Edit View
abcd	0	0	Lister Work In Progress	Edit View

Marketed Product Opportunities

Add New Marketed Product

Product Designation	Therapeutic Class	Mechanism of Action	Indication	Times Viewed	Unique Viewers	Status	Go To
v	Oncologics	v	c	0	0	Lister Work In Progress	Edit View

FIG. 12

1300

Platform Technology Opportunity Search Criteria



There are currently 9 Platform Technology Opportunities.

Technology Field: 1312

All

Application:

All

Listing Company Name:

All

Product Designation:

Opportunities Posted in the Platform:

All 1322

Keyword or Phrase: 1324

Keyword or Phrase:

Keyword or Phrase:

Any or All Keywords:

Any All 1330

1340

1320

1310

1350

SEARCH

FIG. 13

Client 22 15/29 Web Server 56 Application Server 52





FIG. 14A






FIG. 15




FIG. 16

1700

Opportunities Found for Your Search





Category: **Platform Technology Opportunities**

Search Criteria: **All**

1730





1740

1710

Opportunity Code	Product Designation	Listing Company	Technology Field	Application	Buyer Relevance Ratio (out of 10)
TECH11 	Express Array	BioDemo Corp	Microarray	Gene expression	16/18
TECH26 	Receptor Targeted Drug Delivery System (RTDDS)	BioDemo Corp	Drug delivery	Targeted chemotherapy, Targeted drug delivery	13/15

Category: **Discovery Research Opportunities**

Search Criteria: **All**



Opportunity Code	Product Designation	Listing Company	Therapeutic Class	Mechanism of Action	Indication	Development Stage	Buyer Relevance Ratio (out of 4)
DISCRE33  	FR5445	BioDemo Corp	Oncologics	Integrin V5 inhibitor	Solid tumors, Kaposi sarcoma, Rheumatoid arthritis, Psoriasis	Lead Compound(s) Identified	2/4
DISCRE35  	VEGFR3B	BioDemo Corp	Oncologics	anti-VEGF Receptor 3B monoclonal antibody	Solid tumors	In Vitro Proof of Principle	3/4



= Unviewed Opportunity

Category: **Preclinical Opportunities**

Search Criteria: **All**

Opportunity Code	Product Designation	Listing Company	Therapeutic Class	Mechanism of Action	Indication	Development Stage	Buyer Relevance Ratio (out of 10)
PRECLINICAL17  	KIN6543	BioDemo Corp	Oncologics	Inhibitor of neuron-specific mitotic kinesin specifically upregulated in glioblastoma	Glioblastoma	Clinical Regulatory Filing Submitted	12/17

1720

FIG. 17

20/29

1800

Platform Technology Opportunity



Product Designation: **Express Array**
Relevance Ratio: **16/18**

Detail | **Relevance Ratio Scorecard** | **Non-Confidential Packet** | **Add to Favorites**

Company Name	BioDemo Corp
Opportunity Code	TECH11
Date Posted	08/08/2000
Date Last Modified	11/29/2000
Territories Available	USA, All of Europe, Canada, Japan
US PTO Status	Issued - Life Remaining > 10 years
EU/EPO Status	Issued - Life Remaining > 10 years
JP JPO Status	Issued - Life Remaining > 10 years
Composition Of Matter Patent	No
Technology Field	Microarray
Licensee(s)	SRM Genomics Inc., Arritech Biotechnology Corp.
Application	Gene expression
Comments	Complete system for gene expression analysis, including cDNA spotted arrays for mRNA hybridization, hybridization station scanner, and data collection and analysis software. Each chip contains up to 10,000 genes. Chips can be ordered in batches of 100. Standard cancer, inflammation, and metabolism chips for human and mouse genes are available. Exclusive custom chips may be created for an additional fee. Custom services are also available.

Opportunity Lister Information

Name	BioDemo Corp
Type	Pharmaceutical
Phone Number	555-1212
Fax Number	234-231-4441
Website	http://www.quargbiotech.com
Address	1313 Mockingbird Lane
City	Chicago
State/Province	Illinois
Postal Code	94107
Country	USA
Contact Name	Dr. Amanda B. Reconwit
Contact Phone Number	555-1212
Contact Email	webmaster@quargbiotech.com

FIG. 18

Platform Technology Opportunity Relevance Ratio


Product Designation: **TV1126**
 Relevance Ratio: **10/13**

[Detail](#) | [Relevance Ratio Scorecard](#) | [Non-Confidential Packet](#) | [Add to Favorites](#)

Question	Answer	Comments	My Priority	Company Priority
Technology				
Scalable	Yes	Has been produced at 400 g scale with very low variability seen.	Yes	Yes
Specialized instrumentation not required	No		Yes	Yes
Amendable for automation	Yes		Yes	Yes
Special facility not required	Yes		Yes	Yes
Expert know how not required	Yes		Yes	Yes
Specialized training not required	No		Yes	Yes
Pre-packaged	Yes		Yes	Yes
Data published in peer-reviewed journals	Yes	Facility is GMP compliant.	Yes	Yes
Contract Services				
Quality control measures established	Yes		Yes	Yes
Security and confidentiality measures built in	Yes		Yes	Yes
Scalable	No		Yes	Yes
Customized for small scale project	Yes		Yes	Yes
Customized for mass production	N/A		Yes	Yes
System				
Portable across platform	N/A		Yes	Yes
Available for a feasibility studies	N/A		Yes	Yes
Amenable to multi-disciplinary use	N/A		Yes	Yes
24 hour support is available	Yes		Yes	Yes
Supports global multi-site usage	N/A		Yes	Yes

FIG. 19

Edit Platform Technology Priorities



Relevance Ratio Priorities: Platform Technology Opportunities

2010

	2020	My Priority	Company Priority
Technology			
Scalable		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Specialized instrumentation not required		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Amendable for automation		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Special facility not required		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Expert know how not required		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Specialized training not required		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Pre-packaged		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Data published in peer-reviewed journals		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Contract Services			
Quality control measures established		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Security and confidentiality measures built in		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Scalable		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Customized for small scale project		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Customized for mass production		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
System			
Portable across platform		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Available for a feasibility studies		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Amenable to multi-disciplinary use		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
24 hour support is available		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes
Supports global multi-site usage		<input type="checkbox"/> Yes <input type="checkbox"/> No	Yes

SUBMIT

2000

2030

FIG. 20

03755984.01800

23/29

2100

My Personal Profile



2110

- Edit Personal Profile
- Edit Platform Technology Priorities
- Edit Discovery Research Priorities
- Edit Preclinical Priorities
- Edit Clinical Priorities
- Edit Marketed Product Priorities

2120

FIG. 21

24/29

Application Server 52

Web Server 56

Client 22




FIG. 22A

25/29




FIG. 22B

2300

My Opportunity Filters



Platform Technology Opportunities

[Add new filter](#) | [Edit the Relevance Ratio](#)

Name	Technology Field	Application	Keyword or Phrase	Go To
My Filter	Microarray	Gene expression		Edit View Execute

Discovery Research Opportunities

[Add new filter](#) | [Edit the Relevance Ratio](#)

Name	Keyword or Phrase	Go To
pennie	clinical	Edit View Execute

Preclinical Opportunities

[Add new filter](#) | [Edit the Relevance Ratio](#)

Name	Therapeutic Class	Mechanism of Action	Indication	Development Stage	Keyword or Phrase	Go To
------	-------------------	---------------------	------------	-------------------	-------------------	-------

Clinical Opportunities

[Add new filter](#) | [Edit the Relevance Ratio](#)

Name	Therapeutic Class	Mechanism of Action	Indication	Development Stage	Keyword or Phrase	Go To
------	-------------------	---------------------	------------	-------------------	-------------------	-------

Marketed Product Opportunities


[Add new filter](#) | [Edit the Relevance Ratio](#)

Name	Keyword or Phrase	Go To
------	-------------------	-------

FIG. 23

FIG. 23

Platform Technology Opportunity Filter Criteria



2410

Name:

Technology Field:

Application:

Location/Company Name:

Product Designation:

Opportunities Posted in the Previous ...

Keyword or Phrase:

Keyword or Phrase:

Keyword or Phrase:

Any or All Keywords:

☒ Any ☐ All

2420

SAVE FILTER

2430

FIG. 24




FIG. 25A




FIG. 25B